First findings of virtual reality exposure therapy for PTSD

by Robin Reese
The virtual reality exposure therapy involved 30-45 minutes of exposure to virtual environments on a head mounted video display that attempt to match stimuli described by the veteran.

(Medical Xpress)—A randomized controlled clinical trial of Iraq and Afghanistan veterans with post-traumatic stress disorder (PTSD) found that shorter doses of virtual reality exposure therapy (VRE) reduces PTSD diagnoses and symptoms. The study was published in the April 18, 2014 online edition of the American Journal of Psychiatry.

Researchers at Emory University conducted the study with 156 veterans with combat-related PTSD. After an introductory session, each veteran was randomly assigned to receive d-cycloserine (DCS) (53 subjects), alprazolam (50 subjects), or a placebo (53 subjects) before each of five sessions of VRE.

The study found PTSD symptoms significantly improved from pre- to post-treatment with the VRE therapy and the DCS may enhance the VRE results for those veterans who demonstrated better emotional learning in sessions. In addition to self-reported symptoms, researchers used objective measures of cortisol, a stress hormone, and the startle response, and found reductions in reactivity after treatment. Alprazolam, known more commonly as Xanax, impaired recovery from symptoms.

"D-cycloserine, combined with only five sessions of the virtual reality exposure therapy, was associated with significant improvements in objective measures of startle and cortisol and overall PTSD symptoms for those who showed emotional learning in sessions," says lead researcher Barbara Rothbaum, PhD, professor of psychiatry and behavioral sciences at Emory University School of Medicine and director of the Trauma and Anxiety Recovery Program.

This video is not supported by your browser at this time.
Exposure therapy is an evidence-based intervention that has been demonstrated as effective in the treatment of Posttraumatic Stress Disorder (PTSD). During each exposure therapy session, patients repeatedly retell their traumatic experience with the guidance of a trained clinician as well as immersion in a virtual reality simulation. D-Cycloserine, a cognitive enhancer, has been found by Emory researchers to facilitate the extinction of fear that occurs during exposure therapy. One of the pioneers in this type of therapy is Emory's Barbara Rothbaum, PhD, who in this video describes the symptoms of PTSD and the various treatments currently available.

The double-blind, placebo-controlled study consisted of an initial screening assessment, six treatment visits, and follow-up assessments at three, six and 12 months post-treatment. The virtual reality exposure therapy involved 30-45 minutes of exposure to virtual environments on a head mounted video display that attempt to match stimuli described by the veteran. Scenes depict a variety of Iraq and Afghanistan environments, including street scenes and neighborhoods, as well as from different points of view, i.e. as a driver, passenger, or walking on foot. Thirty minutes before each session, participants took a single pill.

"We were very excited to see the substantial gains in self-reported and objective indices of PTSD with only five sessions of the combined," says Rothbaum.

add to favorites email to friend print save as pdf

Related Stories

PTSD psychotherapy is enhanced with D-cycloserine

Jun 04, 2012

Posttraumatic stress disorder (PTSD) is among the most common, distressing, and disabling medical consequences of combat or other extremely stressful life events. The first-line treatment for PTSD is exposure therapy, a type ...

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.